Moteur de recherche d’entreprises européennes
Financement de l’UE (3 744 375 €) : Preparing for RSV Immunisation and Surveillance in Europe Hor28/05/2021 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Preparing for RSV Immunisation and Surveillance in Europe
RSV causes severe disease in the very young and elderly and results in substantial healthcare costs. In the last 4 years, substantial progress has been made in development of products for active and passive immunization against RSV, with 19 products currently in clinical development. In 2017, we were funded by IMI to set up RESCEU project (Grant Agreement number 116019), which is the single largest consortium currently working on RSV and has addressed several of the key evidence gaps to inform the introduction of an RSV vaccine. However, new gaps in evidence have emerged and many key requirements for the introduction of a novel RSV vaccine into national immunisation programmes (not addressed within RESCEU) remain unmet. PROMISE’s vision is to seamlessly build on, exploit, and add value to the significant achievements of RESCEU to prepare for the imminent introduction of an RSV vaccine. Expanding the existing RESCEU network to include 5 new partners, PROMISE comprises of 5 distinct but inter-connected work packages (WPs). WP 1 will conduct epidemiological and cost-effectiveness analyses marshalling data from systematic reviews; national and regional disease registries; surveillance programmes and linked routine healthcare datasets. WP2 will foster a consensus and develop an operational plan for expanded coordinated RSV surveillance and reporting activities; post-licensure monitoring and evaluation of products for RSV immunization across Europe. WP3 will initiate new prospective studies to address key gaps in existing knowledge (RSV disease severity scores, asthma in school age children) and assemble biobanks for biomarker validation. WP4 will validate temporally and at mucosal level biomarkers that were identified in RESCEU adopting state of the art technologies. WPs 1-4 will develop high-quality, sustainable, robust data collection systems that link closely with public health/regulatory bodies/health care providers for informing policy and regulatory processes.
| Astrazeneca AB | 0,00 € |
| Fondazione Penta ETS | 53 750 € |
| Fundacion para El Fomento de La Investigacion Sanitaria y Biomedica de La Comunitat Valenciana | 67 500 € |
| Glaxosmithkline Biologicals SA | 0,00 € |
| Imperial College of Science Technology and Medicine | 305 000 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| MARTIN-LUTHER-UNIVERSITAT HALLE-WITTENBERG | 98 750 € |
| NOVAVAX Inc. | 0,00 € |
| Pfizer Ltd. | 0,00 € |
| RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU | 358 125 € |
| Sanofi Pasteur SA | 0,00 € |
| Servizo Galego de Saude | 67 500 € |
| Statens Serum Institut | 150 000 € |
| STICHTING NEDERLANDS INSTITUUT VOOR ONDERZOEK VAN DE GEZONDHEIDSZORG | 129 375 € |
| STICHTING RESVINET | 84 375 € |
| Teamit Research SL | 587 125 € |
| TERVEYDEN JA HYVINVOINNIN LAITOS | 170 625 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 203 750 € |
| The University of Edinburgh | 746 625 € |
| UNIVERSITAIR MEDISCH CENTRUM UTRECHT | 470 000 € |
| Universiteit Antwerpen | 95 000 € |
| VARSINAIS-SUOMEN HYVINVOINTIALUE | 126 915 € |
| VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA | 29 960 € |
https://cordis.europa.eu/project/id/101034339
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Astrazeneca AB - Financement de l’UE (3 744 375 €) : Preparing for RSV Immunisation and Surveillance in Europe"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
